Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.
about
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal CanadiansTreatment responses in Asians and Caucasians with chronic hepatitis C infectionResults of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b.Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.Pegaferon in hepatitis C: Results of a Multicenter StudySuperior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.Predicting the probable outcome of treatment in HCV patients.Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study.Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination TherapyA reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China.High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patientsRacial disparity in liver disease: Biological, cultural, or socioeconomic factors.Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.Individualization of chronic hepatitis C treatment according to the host characteristics.Management of nonresponsive hepatitis C.Systematic review: epidemiology of hepatitis C genotype 6 and its management.The impact of ethnicity on hepatitis C virus treatment decisions and outcomes.Systematic review: Asian patients with chronic hepatitis C infection.Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review.Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment.Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.Characterization of the Asian Phenotype - An Emerging Paradigm with Clinicopathological and Human Research Implications.The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial.Body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis C.Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern India.Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India.Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.Acute hepatitis C in Korea: different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion.
P2860
Q27488260-6823E46E-52B0-4E16-AB71-705C74AF2848Q27489011-B956C1A2-556D-47F0-9D0F-B55FE817A553Q30151392-907EA7EA-8AAD-4E68-89A2-1582912836B1Q31149778-3BB5E46C-D913-4711-B41E-FE67725AC416Q33938574-AA55CE47-9C18-43A4-9836-8A8B9262560BQ34134994-6CE9E235-7997-4836-803E-BF451A2953B0Q34365442-4B0E4678-0EA7-4D99-8DCA-C5075694AE4FQ34409039-2D43D76C-EB05-4984-B50E-F5BDE12D6006Q34621423-0E005478-29BA-4B97-B9B3-5E755A059F85Q35042843-B1A1A1B0-5CA5-41CA-88F1-1D24431127B4Q35778355-4DFD545B-CF81-49D3-BB2D-1D7D0DBC66F4Q36184075-9207C432-23B5-4548-A78B-0CC907CEE4A7Q36306694-7C775633-9E49-48FB-A97A-1A85D829427CQ36680950-6951B6AF-471A-4775-B792-638C820117CDQ36756380-39C3CE40-1279-4B53-BD03-658E4571D283Q36983527-458C61BE-9897-42AB-977E-CB1E7562BE0AQ37095472-2EDD365A-43DD-4835-9BAE-A2D99EE455FBQ37478964-F7F7343A-C7EB-48F3-83F1-2414C601AD36Q37646759-8A91755A-6356-45DD-858F-D820143BFEDCQ37654502-2F4D7D8E-0F0C-4F1B-AFFE-32D1F19275D2Q37727164-F87AD0AD-1954-42F8-A694-DF90FD9B7BF6Q37882006-FCAB2035-9B7D-4995-AFD1-0623E06D9551Q38052034-0F399E96-28A6-455F-899E-D03F2D30C140Q38096012-7730758E-EB38-4F5A-9A14-F42B66B06234Q38098579-CD79ECC5-6385-486A-8138-916CABFEA2F0Q38121422-D8C096FD-7E32-4321-8C43-14F4C55F9A67Q39146830-385C5880-49C3-4277-8ACC-B4E85524BFF9Q39254698-7A5A4F38-4510-49D7-83F7-4580B17DC8F3Q40077202-41FAD7FE-F74A-45A4-927D-36F9450B6779Q40706760-5DC40A58-2F3F-4109-B493-C9FD5961E2BAQ41912262-74C25516-7E89-422B-B5CB-612748B36D4DQ42172799-31751CC8-8FD1-471F-BBBD-47AC6CB20642Q42232204-16E0CDB8-FCA6-42F3-9289-A96DC07ECDB4Q42252312-6AC9636C-20BC-4975-9739-224AEC8BC10FQ42980276-D8DBA554-F451-4FEF-9B90-A05CE809C511Q42981999-BDB0C0AE-334A-4D6F-8C92-71A32C98DFDBQ42982312-AE5C046D-B570-4051-ACFB-F4F965F73667Q42996032-369A5CE4-26B1-495C-A059-DEF9286ECC65Q43001794-58197727-FE75-4EE4-8A94-56554102442BQ43036767-34D171DF-FED1-4026-9A67-CEEA596EACF3
P2860
Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@en
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@nl
type
label
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@en
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@nl
prefLabel
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@en
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@nl
P2093
P2860
P1476
Impact of asian race on respon ...... avirin in chronic hepatitis C.
@en
P2093
Canadian Pegasys Expanded Access Group
Jenny Heathcote
Kamran Khan
Sharif Missiha
P2860
P304
P356
10.1111/J.1572-0241.2007.01431.X
P407
P577
2007-07-19T00:00:00Z